Anika Therapeutics (NASDAQ: ANIK) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Anika Therapeutics and Biogen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 0 1 0 3.00
Biogen 0 10 17 1 2.68

Anika Therapeutics presently has a consensus target price of $57.00, suggesting a potential upside of 6.66%. Biogen has a consensus target price of $345.54, suggesting a potential upside of 8.02%. Given Biogen’s higher probable upside, analysts plainly believe Biogen is more favorable than Anika Therapeutics.

Volatility & Risk

Anika Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Institutional and Insider Ownership

84.9% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 88.3% of Biogen shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Anika Therapeutics and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 28.23% 13.40% 12.41%
Biogen 29.44% 38.51% 20.80%

Earnings and Valuation

This table compares Anika Therapeutics and Biogen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $103.38 million 7.58 $32.54 million $2.13 25.09
Biogen $11.45 billion 5.91 $3.70 billion $16.31 19.61

Biogen has higher revenue and earnings than Anika Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Anika Therapeutics on 10 of the 15 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

About Biogen

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company’s product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.